Back to Search
Start Over
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
- Source :
- Molecular Imaging and Radionuclide Therapy, Molecular Imaging and Radionuclide Therapy, Vol 29, Iss 3, Pp 98-104 (2020)
- Publication Year :
- 2020
- Publisher :
- Galenos Publishing, 2020.
-
Abstract
- Objectives In this study, we aimed to investigate whether Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scanning is adequate to predict intermediate risk, high risk, or oligometastatic prostate cancer (PCa) as an initial staging modality. Methods The Ga-68 PSMA PET/CT scan images of 50 PCa patients pathologically proven by transrectal ultrasound guided biopsy were evaluated retrospectively. The association of standard uptake value maximum (SUVmax) value of the area with the highest PSMA expression within the primary tumor with the risk groups and metastatic burden is investigated. Results The SUVmax value was 6.18 in oligometastatic patients where it was measured as 10.93 in patients with higher metastatic burden (p=0.037). The cut-off SUVmax value for multiple metastases was 7.96 (p=0.047). According to the regression model, SUVmax value has a positive influence [odds ratio (OR)=1.42], which was statistically significant (p=0.038). SUVmax values for intermediate and high risk patients were 6.91 and 11.44, respectively (p=0.014). The cut-off SUVmax value for the high risk group was 10.55 (p=0.006). In the regression model, SUVmax value has a positive influence (OR=1.198), which was statistically significant (p=0.021). Conclusion In this paper, we demonstrated the association between SUVmax value of primary tumor and Gleason score. Our results also allowed us to suggest that primary tumor SUVmax is a sufficiently accurate predictor of D'Amico risk groups in newly diagnosed PCa cases. Additionally, Ga-68 PSMA PET/CT turns out to be a useful tool in determining oligometastatic PCa, which requires a different treatment approach.
- Subjects :
- lcsh:Medical physics. Medical radiology. Nuclear medicine
lcsh:R895-920
Ga-68 PSMA PET/CT
030232 urology & nephrology
lcsh:Medicine
Standardized uptake value
urologic and male genital diseases
030218 nuclear medicine & medical imaging
03 medical and health sciences
Prostate cancer
0302 clinical medicine
medicine
Radiology, Nuclear Medicine and imaging
In patient
Psma pet ct
lcsh:R5-920
medicine.diagnostic_test
business.industry
lcsh:R
SUVmax
Odds ratio
medicine.disease
prostate cancer
Primary tumor
oligometastasis
Positron emission tomography
Original Article
Transrectal ultrasound guided biopsy
lcsh:Medicine (General)
business
Nuclear medicine
Subjects
Details
- Language :
- English
- ISSN :
- 21471959 and 21461414
- Volume :
- 29
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Molecular Imaging and Radionuclide Therapy
- Accession number :
- edsair.doi.dedup.....eb4c24615abe5f251dea7eb18a2caed2